CD274 and head and neck squamous cell carcinoma: There are several types of biomarkers that are being investigated for their potential use in predicting response to immunotherapy in HNSCC patients, including tumor mutational burden, PD-L1 expression, tumor-infiltrating lymphocytes, immune gene structures, and circulating tumor DNA [63].